TrialClinical cancer research : an official journal of the American Association for Cancer Research2020

Ibrutinib Treatment for First-Line and Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Analysis of the Pivotal Phase Ib/II PCYC-1102 Study.

John C Byrd et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.